BACKGROUND: Effects of lifestyle change on blood glucose levels can be monitored by self-monitoring of blood glucose (SMBG) in type 2 diabetes mellitus (T2DM) patients. We analyzed whether the SMBG-structured lifestyle intervention program ROSSO-in-praxi-international can improve glucometabolic control in the short and the long term. SUBJECTS AND METHODS: One hundred twenty-four SMBG-naive ambulatory non-insulin-treated T2DM patients were randomly assigned to an SMBG group (n=63) and a control group (n=61). Both groups received a 12-week structured lifestyle guidance manual. The SMBG group additionally got a blood glucose meter with 150 test strips and was instructed to measure blood glucose regularly as well as event-driven. Glucometabolic parameters were assessed at baseline, after 12 weeks, and after 1.5 years. RESULTS: During the 12 weeks of intervention the SMBG group significantly improved glycated hemoglobin (HbA1c) levels (from 7.4 ± 1.6% to 6.9 ± 1.1% [P<0.001]) and weight (-0.9 ± 1.9 kg [P<0.05]), whereas HbA1c reduction (from 7.5 ± 1.0% to 7.3 ± 1.0%) and weight loss (-0.6 ± 2.4 kg) were not significant in the control group. Of the 124 patients, 122 completed the 1.5-year follow-up. In the control group HbA1c increased again, reaching baseline values (7.5 ± 0.7%). In the SMBG group HbA1c remained stable (6.9 ± 0.9% [P=0.0003 for trend]), and weight (-1.6 ± 3.0 kg vs. baseline [P=0.0003 for trend]) improved further. Eighty-seven percent of participants in the SMBG group continued to perform SMBG. Those who measured their blood glucose more than three times per week (n=24) demonstrated an overall reduction in HbA1c of 1.0% (P=0.006 vs. three times or fewer per week) after 1.5 years. CONCLUSIONS: Integration of SMBG into basic therapy of T2DM for monitoring the effect of lifestyle changes improves glucometabolic control and has long-term effects.
RCT Entities:
BACKGROUND: Effects of lifestyle change on blood glucose levels can be monitored by self-monitoring of blood glucose (SMBG) in type 2 diabetes mellitus (T2DM) patients. We analyzed whether the SMBG-structured lifestyle intervention program ROSSO-in-praxi-international can improve glucometabolic control in the short and the long term. SUBJECTS AND METHODS: One hundred twenty-four SMBG-naive ambulatory non-insulin-treated T2DM patients were randomly assigned to an SMBG group (n=63) and a control group (n=61). Both groups received a 12-week structured lifestyle guidance manual. The SMBG group additionally got a blood glucose meter with 150 test strips and was instructed to measure blood glucose regularly as well as event-driven. Glucometabolic parameters were assessed at baseline, after 12 weeks, and after 1.5 years. RESULTS: During the 12 weeks of intervention the SMBG group significantly improved glycated hemoglobin (HbA1c) levels (from 7.4 ± 1.6% to 6.9 ± 1.1% [P<0.001]) and weight (-0.9 ± 1.9 kg [P<0.05]), whereas HbA1c reduction (from 7.5 ± 1.0% to 7.3 ± 1.0%) and weight loss (-0.6 ± 2.4 kg) were not significant in the control group. Of the 124 patients, 122 completed the 1.5-year follow-up. In the control group HbA1c increased again, reaching baseline values (7.5 ± 0.7%). In the SMBG group HbA1c remained stable (6.9 ± 0.9% [P=0.0003 for trend]), and weight (-1.6 ± 3.0 kg vs. baseline [P=0.0003 for trend]) improved further. Eighty-seven percent of participants in the SMBG group continued to perform SMBG. Those who measured their blood glucose more than three times per week (n=24) demonstrated an overall reduction in HbA1c of 1.0% (P=0.006 vs. three times or fewer per week) after 1.5 years. CONCLUSIONS: Integration of SMBG into basic therapy of T2DM for monitoring the effect of lifestyle changes improves glucometabolic control and has long-term effects.
Authors: Teresa Ruiz Gracia; Nuria García de la Torre Lobo; Alejandra Durán Rodríguez Hervada; Alfonso L Calle Pascual Journal: World J Diabetes Date: 2014-08-15
Authors: Susan M Schembre; Michelle R Jospe; Edward J Bedrick; Liang Li; Abenaa M Brewster; Erma Levy; Danika D Dirba; Morgan Campbell; Rachael W Taylor; Karen M Basen-Engquist Journal: Cancer Prev Res (Phila) Date: 2022-03-01
Authors: Ruth S Weinstock; Barbara H Braffett; Paul McGuigan; Mary E Larkin; Nisha B Grover; Natalie Walders-Abramson; Lori M Laffel; Christine L Chan; Nancy Chang; Beth E Schwartzman; Rose Ann Barajas; Nicole Celona-Jacobs; Morey W Haymond Journal: Diabetes Care Date: 2019-03-04 Impact factor: 19.112
Authors: Andreas Pfützner; Stephanie Strobl; Filiz Demircik; Lisa Redert; Johannes Pfützner; Anke H Pfützner; Alexander Lier Journal: J Diabetes Sci Technol Date: 2018-02-16
Authors: Deborah A Greenwood; Shelley A Blozis; Heather M Young; Thomas S Nesbitt; Charlene C Quinn Journal: J Med Internet Res Date: 2015-07-21 Impact factor: 5.428
Authors: Adam Steventon; Martin Bardsley; Helen Doll; Elizabeth Tuckey; Stanton P Newman Journal: BMC Health Serv Res Date: 2014-08-06 Impact factor: 2.655